ICML 2019 | Venetoclax plus dose-adjusted R-EPOCH for Richter’s: results of the CRC043 trial

Matthew Davids

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the CRC043 trial (NCT03054896), a Phase II study of venetoclax in combination with dose-adjusted R-EPOCH for patients with Richter’s syndrome. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video